What is BDTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BDTX?

P/E (TTM) is n/a and 52-week range is $1.60 to $4.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BDTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BDTX?

The company profile lists net income (TTM) near $-43M, EPS (TTM) near $-0.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Black Diamond Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 57.3M shares outstanding, ISIN US09203E1055 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Black Diamond Therapeutics Inc

$BDTX

Health Care · Biotechnology

IR Run Scenarios

$1.83

+1.10%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Employees

Website

www.blackdiamondtherapeutics.com/

IPO

2020-01-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)